CTIS2023-503270-20-00进行中（未招募）1 期
GORTEC 2023-01
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteersPrevention of atherothrombotic events in adult patients with- acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventMedDRA version: 20.0Level: PTClassification code: 10028596Term: Myocardial infarction Class: 100000004849CTIS2023-504116-14-00Celon Pharma S.A.40
招募中
1 期
A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTSmetabolic bone diseasesMedDRA version: 20.0Level: SOCClassification code: 10028395Term: Musculoskeletal and connective tissue disorders Class: 17CTIS2023-503866-22-00Mesentech Inc.72
进行中（未招募）
1 期
Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.healthy volunteerCTIS2023-507599-34-00Geiser Pharma S.L.60
招募中
1 期
A Phase 1b Study of Imvotamab in Severe Systemic Lupus ErythematosusSystemic Lupus ErythematosusCTIS2023-506499-29-00IGM Biosciences Inc.18
进行中（未招募）
1 期
First administration in healthy volunteers of a single and increasing dose of a new molecule for the treatment of brain diseasesPost-Traumatic Stress Disorder (PTSD)MedDRA version: 21.1Level: PTClassification code: 10036316Term: Post-traumatic stress disorder Class: 100000004873CTIS2023-505030-99-00Rest Therapeutics36